SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001867096-24-000053
Filing Date
2024-04-23
Accepted
2024-04-23 16:24:37
Documents
20
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A xers-20240423.htm   iXBRL DEF 14A 861238
3 xers-20240423_g1.jpg GRAPHIC 16155
4 xers-20240423_g2.jpg GRAPHIC 37016
5 xers-20240423_g3.jpg GRAPHIC 10765
6 xers-20240423_g4.jpg GRAPHIC 33913
7 xers-20240423_g5.jpg GRAPHIC 79754
8 xers-20240423_g6.jpg GRAPHIC 72934
9 xers-20240423_g7.jpg GRAPHIC 77293
10 xers-20240423_g8.jpg GRAPHIC 2589175
11 xers-20240423_g9.jpg GRAPHIC 563483
  Complete submission text file 0001867096-24-000053.txt   9936719

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20240423.xsd EX-101.SCH 930
23 EXTRACTED XBRL INSTANCE DOCUMENT xers-20240423_htm.xml XML 125461
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40880 | Film No.: 24865128
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)